- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07335198
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
En fase 1, randomisert, placebokontrollert, dobbelblind, parallellgruppestudie for å evaluere sikkerheten, toleransen, farmakokinetikken og immunogeniteten til efimosfermin alfa administrert som en enkeltdose til friske deltakere av kinesisk, japansk og hvit/europeisk opprinnelse
This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of Chinese, Japanese, and White/European ancestry.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Auckland, New Zealand, 1010
- GSK Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Participants who are generally healthy as determined by medical evaluation
- Body weight at least 50.0 kilograms (kg) for male participants or at least 45.0 kg for female participants
- Body mass index (BMI) within the range of 18.0 to 28.0 kilograms per square meter (kg/m^2) (inclusive)
- Male and female participants
- Participants of Chinese ancestry are eligible if born in mainland China, Hong Kong, or Taiwan, and descendant of 2 ethnic Chinese parents and 4 ethnic Chinese grandparents; and have lived outside China, Hong Kong, or Taiwan for less than 10 years at the time of screening.
- Participants of Japanese ancestry are eligible if born in Japan and descendant of 2 ethnic Japanese parents and 4 ethnic Japanese grandparents; and have lived outside Japan for less than 10 years at the time of screening.
- Participants of White/European ancestry are eligible if self-identified as being of White/European ancestry, (that is [i.e.], from the original peoples of Europe) irrespective of current place of residence; and descendant of 2 parents and 4 grandparents of White/European ancestry (i.e., from the original peoples of Europe) irrespective of place of birth or current place of residence.
Exclusion Criteria:
- History or presence of disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
- Current or chronic history of liver or biliary disease with the exception of Gilbert's syndrome or asymptomatic gallstones.
- History of pancreatic injury, pancreatitis or other pancreatic disease; history of Type one Diabetes Mellitus (T1DM) or positive glutamic acid decarboxylase auto-antibodies, or major Type two Diabetes Mellitus (T2DM) complications including severe gastroparesis and autonomic neuropathy.
- Abnormal blood pressure (defined as systolic Blood Pressure [BP] more than equal [>=]140 millimeters of mercury [mmHg] or diastolic BP >=90 mmHg measured based on the average of triplicate BP readings).
- History of metabolic bone disorders including osteoporosis, osteopenia, or osteomalacia.
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years.
- Alanine transaminase (ALT) more than (>)1.5 * upper limit of normal (ULN).
- Total bilirubin >1.5 * ULN
- Known bleeding disorder.
- History of immunodeficiency diseases, including a positive test result for human immunodeficiency virus (HIV).
- Corrected QT Interval using Fridericia's Formula (QTcF) >=450 millisecond (msec)(male) or >=470 msec (female) at Screening Visit based on the average of triplicate ECGs.
- Use of statins, other lipid lowering medications or hypertension medications unless on a stable dose for at least 3 months.
- Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever was longer; or longer if required by local regulations.
- Participants who have received native FGF21 or a FGF21 analog at any time in the past.
- Intended use of over the counter (OTC) or prescription medication (including herbal medications) within 7 days prior to dosing and for the duration of study participation.
- Live vaccine within 14 days prior to dosing and non-live vaccines for 7 days prior study dosing.
- Current enrolment or participation in another clinical trial within the last 30 days before signing consent of current study.
- Presence of hepatitis B surface antigen (HBsAg) or hepatitis C antibody at screening or within 3 months prior to the first dose of study intervention
- A positive pre-study drug/alcohol screen
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Efimosfermin alfa in participants of Chinese Ancestry
Healthy participants of Chinese ancestry will be randomized to receive efimosfermin alfa. |
Efimosfermin alfa to be administered |
|
Eksperimentell: Efimosfermin alfa in participants of Japanese Ancestry
Healthy participants of Japanese ancestry will be randomized to receive efimosfermin alfa. |
Efimosfermin alfa to be administered |
|
Eksperimentell: Efimosfermin alfa in participants of White/European Ancestry
Healthy participants of White/European ancestry will be randomized to receive efimosfermin alfa. |
Efimosfermin alfa to be administered |
|
Placebo komparator: Placebo in participants of Chinese Ancestry
Healthy participants of Chinese ancestry will be randomized to receive Placebo. |
Placebo to be administered |
|
Placebo komparator: Placebo in participants of Japanese Ancestry
Healthy participants of Japanese ancestry will be randomized to receive Placebo. |
Placebo to be administered |
|
Placebo komparator: Placebo in participants of White/European Ancestry
Healthy participants of White/European ancestry will be randomized to receive Placebo. |
Placebo to be administered |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Antall deltakere med bivirkninger (AEs), behandlingsrelaterte bivirkninger og alvorlige bivirkninger (SAEs)
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
|
Antall deltakere med klinisk signifikante endringer i hematologi-, kjemi- og urinanalyseparametere
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
|
Antall deltakere med klinisk signifikante endringer i 12-leders elektrokardiogram (EKG)
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
|
Antall deltakere med klinisk signifikante endringer i vitale tegn
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
|
Arealet under serumlegemiddelkonsentrasjon-kurven mot tid fra tid null til tidspunktet for den siste kvantifiserbare konsentrasjonen (AUC[0-t]) av efimosfermin alfa
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
|
Arealet under kurven for serumkonsentrasjon av legemiddel mot tid fra tid null ekstrapolert til uendelig (AUC[0-inf]) for efimosfermin alfa
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
|
Maksimal observert serumkonsentrasjon av legemiddelet, bestemt direkte fra serumkonsentrasjon-tid-dataene (Cmax) for efimosfermin alfa
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Tid til maksimal observert serumkonsentrasjon av medikament (Tmax) for efimosfermin alfa
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
|
Tilsynelatende terminal halveringstid (t1/2) for efimosfermin alfa
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
|
Arealet under serum legemiddelkonsentrasjon versus tid kurven fra tid null til 90 dager [AUC(0-90dager)] av efimosfermin alfa
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
|
Tidspunkt for siste kvantifiserbare plasmamedikamentkonsentrasjon (Tlast) av efimosfermin alfa
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
|
Tilsynelatende klaring (CL/F) av efimosfermin alfa
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
|
Tilsynelatende distribusjonsvolum (Vz/F) av efimosfermin alfa
Tidsramme: Opptil 90 dager
|
Opptil 90 dager
|
|
Area under the serum drug concentration versus time curve from time zero to 45 days [AUC(0-45days)] of efimosfermin alfa
Tidsramme: Up to 45 days
|
Up to 45 days
|
|
Area under the serum drug concentration versus time curve from time zero to 60 days [AUC(0-60days)] of efimosfermin alfa
Tidsramme: Up to 60 days
|
Up to 60 days
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 301158
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD-delingstidsramme
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Tilgangskriterier for IPD-deling
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .